Fundraising Fox
/Companies
Sign in

Imvaria San Francisco

Berkeley, US · Founded 2019 · 8 employees on LinkedIn · 5 known investors

Find your way into Imvaria San Francisco

Sign up to see every warm intro you have to Imvaria San Francisco

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Imvaria San Francisco team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

IMVARIA develops AI-driven software-as-medical-device solutions that analyze medical imaging and data to provide non-invasive diagnostic assessments for lung diseases, including idiopathic pulmonary fibrosis and interstitial lung disease. The company's FDA-authorized tools serve pulmonologists and other clinicians to reduce the need for invasive biopsy testing.

AI & Machine LearningHealthtechMedical Devices

Founders & leadership

Imvaria San Francisco was founded in 2019 by Joshua Reicher and Michael Muelly.

JR
Joshua ReicherCo-founder & CEO
MMMichael Muelly
Michael MuellyCo-founder & CTODr. Michael Muelly is Co-founder and CTO of IMVARIA, which develops AI software for analyzing medical imaging to diagnose lung diseases. He holds expertise in radiology and computer science.

Investors · 5

Creative Ventureslisted by Creative VenturesSan Francisco Bay Area · $1M

How we know: Creative Ventures's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

InHealth Ventureslisted by InHealth VenturesLondon · $500K – $3M

How we know: InHealth Ventures's portfolio page · Not right? Tell us

Meridian Street Capitallisted by Meridian Street CapitalNew York · $100K – $5Mvia Scott Law · inferred

How we know: the VCSheet dataset · Not right? Tell us

StartXlisted by StartXStanford · $10K – $1M

How we know: StartX's portfolio page · Not right? Tell us

Related companies · 4

IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
AlvariaAlvaria provides a compliance and communication platform for organizations conducting outreach. The company serves enterprises needing to manage customer interactions while maintaining regulatory compliance.
ItnonlineImaging Technology News is a trade publication that reaches over 34,000 radiology, radiation oncology, women's health, and nuclear medicine professionals with editorial content and product comparison tools. The publication serves as a primary resource for healthcare technology purchasing decisions within medical imaging specialties.
Vida LungVIDA provides imaging data collection and AI-powered analysis services to life sciences companies for accelerating drug development and clinical trials. The company serves therapeutic researchers and clinical development teams in the biotech and pharmaceutical sectors.

Companies working in the same space as Imvaria San Francisco.

Frequently asked questions

What does Imvaria San Francisco do?
IMVARIA develops AI-driven software-as-medical-device solutions that analyze medical imaging and data to provide non-invasive diagnostic assessments for lung diseases, including idiopathic pulmonary fibrosis and interstitial lung disease. The company's FDA-authorized tools serve pulmonologists and other clinicians to reduce the need for invasive biopsy testing.
Who founded Imvaria San Francisco?
Imvaria San Francisco was founded by Joshua Reicher, Michael Muelly in 2019.
Who are Imvaria San Francisco's investors?
Imvaria San Francisco's investors include CloudStone Capital, Creative Ventures, InHealth Ventures, Meridian Street Capital, StartX.
Where is Imvaria San Francisco headquartered?
Imvaria San Francisco is headquartered in Berkeley, US.